Navigation Links
Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
Date:2/21/2012

AMSTERDAM, The Netherlands, February 21, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has received a request to provide additional information to the Committee for Human Medicinal Products (CHMP) on Glybera® (alipogene tiparvovec) by March 8, 2012. The CHMP request follows the announcement on January 30, 2012 that the European Commission Standing Committee was requesting additional information from the CHMP. The CHMP has indicated that a final decision on Glybera could be made by May 2012.

Glybera is a gene therapy for patients with the genetic disorder LPLD, a very rare inherited condition that is associated with increased levels of chylomicrons. These particles carry certain types of fat in the blood, which because they are not removed from the body can cause recurrent bouts of pancreatitis. There is no treatment currently available for these patients.

On October 23, 2011, AMT received a non-approvable opinion from the CHMP (following a re-examination of the marketing approval dossier originally rejected in June 2011) despite a recommendation to approve Glybera by the Committee for Advanced Therapies (CAT). The CAT is an expert body implemented by the European Commission to prepare and advise the CHMP on decisions regarding advanced therapeutics, in particular gene and cell therapies. 

AMT's proposed acquisition of assets by uniQure BV announced on February 17, 2012, was developed on the basis that Glybera is not approvable. This transaction will proceed as planned. In the event that Glybera could be commercialized in Europe, uniQure will evaluate how achieving this important milestone could be realized most efficiently.

About Glybera®

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency.

LPLD is an orphan disease for which no treatment ex
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
2. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
3. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
4. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
5. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
6. Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
7. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
8. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
10. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
11. Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2
... ... ultrafiltration, NEW ... today that it will be exhibiting its Dual Stage,Ultrafilter products ... conference in Denver, Colorado, June,15th-19th, 2008. Building on the success ...
... BD (Becton,Dickinson and Company) (NYSE: BDX ), ... present at the Goldman Sachs Twenty-Ninth,Annual Global Healthcare Conference ... The live webcast of BD,s presentation can be accessed ... will be available for replay,through Wednesday, June 18, 2008., ...
... June 3 HLTH Corporation,(Nasdaq: HLTH ) ... definitive,agreement to sell its ViPS segment to General ... Dynamics Corporation,(NYSE: GD ) for $225 million ... conditions, including the expiration or termination of the ...
... can produce tiny magnetic nuggets after the introduction of ... gene MagA could become a valuable tool for tracking ... (MRI), says Xiaoping Hu, PhD, professor of biomedical engineering ... , "We have found a very simple way to ...
... N.Y., June 3 MedAmerica reports 2007 was ... results. In,addition, MedAmerica outperformed the long-term care insurance ... annual sales rate of 10%. (LIMRA 2007), ... Rochester, NY),MedAmerica Insurance Company (Home Office: Pittsburgh, PA), ...
... On June 7, 2008 the Philadelphia,Physicians for Student ... in the Philadelphia School District. Student,athletes in Pennsylvania ... eligible,to compete in interscholastic activities. The standard physicals ... enough to identify some potentially,life-threatening conditions., The ...
Cached Medicine News:Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 2Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 3Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 4Health News:HLTH Announces Agreement to Sell ViPS Unit to General Dynamics for $225 Million 2Health News:HLTH Announces Agreement to Sell ViPS Unit to General Dynamics for $225 Million 3Health News:Philly's Top Doc's Organize to Help Prevent Young Athlete Deaths in Philadelphia 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: